image
Healthcare - Biotechnology - NASDAQ - US
$ 2.77
-5.14 %
$ 298 M
Market Cap
-1.05
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one RCKT stock under the worst case scenario is HIDDEN Compared to the current market price of 2.77 USD, Rocket Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one RCKT stock under the base case scenario is HIDDEN Compared to the current market price of 2.77 USD, Rocket Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one RCKT stock under the best case scenario is HIDDEN Compared to the current market price of 2.77 USD, Rocket Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RCKT

image
$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.0$6.0$6.0$4.0$4.0$2.0$2.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-273 M OPERATING INCOME
-5.22%
-259 M NET INCOME
-5.35%
-210 M OPERATING CASH FLOW
-7.60%
132 M INVESTING CASH FLOW
234.30%
186 M FINANCING CASH FLOW
-10.87%
0 REVENUE
0.00%
-64.4 M OPERATING INCOME
-2.70%
-61.3 M NET INCOME
-1.67%
-55.8 M OPERATING CASH FLOW
-18.85%
-58 M INVESTING CASH FLOW
-53.24%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Rocket Pharmaceuticals, Inc.
image
Current Assets 378 M
Cash & Short-Term Investments 372 M
Receivables 0
Other Current Assets 5.85 M
Non-Current Assets 150 M
Long-Term Investments 0
PP&E 83.3 M
Other Non-Current Assets 66.2 M
70.56 %15.79 %12.54 %Total Assets$527.7m
Current Liabilities 40.7 M
Accounts Payable 0
Short-Term Debt 2.86 M
Other Current Liabilities 37.8 M
Non-Current Liabilities 23.8 M
Long-Term Debt 0
Other Non-Current Liabilities 23.8 M
4.43 %58.68 %36.89 %Total Liabilities$64.5m
EFFICIENCY
Earnings Waterfall Rocket Pharmaceuticals, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 273 M
Operating Income -273 M
Other Expenses -14.5 M
Net Income -259 M
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)000(273m)(273m)14m(259m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-55.86% ROE
-55.86%
-49.03% ROA
-49.03%
-55.77% ROIC
-55.77%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Rocket Pharmaceuticals, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -259 M
Depreciation & Amortization 9.38 M
Capital Expenditures -5.86 M
Stock-Based Compensation 43.9 M
Change in Working Capital 1.92 M
Others -4.27 M
Free Cash Flow -216 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Rocket Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for RCKT of $26.4 , with forecasts ranging from a low of $2 to a high of $45 .
RCKT Lowest Price Target Wall Street Target
2 USD -27.80%
RCKT Average Price Target Wall Street Target
26.4 USD 853.67%
RCKT Highest Price Target Wall Street Target
45 USD 1524.55%
Price
Max Price Target
Min Price Target
Average Price Target
454540403535303025252020151510105500Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 20
6. Ownership
Insider Ownership Rocket Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
129 K USD 6
3-6 MONTHS
378 K USD 5
6-9 MONTHS
343 K USD 6
9-12 MONTHS
422 K USD 6
Bought
102 K USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT) Over Possible Securities Fraud NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease. accessnewswire.com - 1 week ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT). Investors who purchased Rocket securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCKT. accessnewswire.com - 1 week ago
Investigation Opened on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders - Contact Levi & Korsinsky NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease. accessnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 week ago
Levi & Korsinsky Launches Fraud Investigation on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announcing an update related to RP-A501, its investigational gene therapy for Danon disease. accessnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 week ago
Potential Securities Fraud: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT) NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease. accessnewswire.com - 1 week ago
Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Stockholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT). Investors who purchased Rocket securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCKT. accessnewswire.com - 1 week ago
Levi & Korsinsky Launches Fraud Investigation on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease. accessnewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Rocket Pharmaceuticals, Inc. (RCKT) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT). Investors who purchased Rocket securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCKT. accessnewswire.com - 2 weeks ago
RCKT ALERT: Ongoing Investigation Into Rocket Pharmaceuticals, Inc. - Contact Levi & Korsinsky NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease. accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 weeks ago
8. Profile Summary

Rocket Pharmaceuticals, Inc. RCKT

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 298 M
Dividend Yield 0.00%
Description Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Contact 9 Cedarbrook Drive, Cranbury, NJ, 08512 https://rocketpharma.com
IPO Date Feb. 18, 2015
Employees 299
Officers Dr. Kinnari Patel M.B.A., Pharm.D. Head of R&D, President & Chief Operating Officer Kevin Giordano Director of Corporate Communications Ms. Sarbani Chaudhuri M.B.A. Chief Commercial & Medical Affairs Officer Mr. Aaron Ondrey Chief Financial Officer Dr. Gaurav D. Shah M.D. Chief Executive Officer & Director Dr. Jonathan Schwartz M.D. Chief Medical & Gene Therapy Officer Dr. Gayatri R. Rao J.D., M.D. Senior Vice President of Clinical Safety & Chief Regulatory Officer Ms. Isabel Carmona J.D. Chief People Officer Mr. Martin Louis Wilson J.D. General Counsel, Chief Compliance Officer & Chief Corporate Officer Mr. Raj Prabhakar M.B.A. Chief Business Officer